Harrow, Inc. (HROW)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Harrow, Inc. (HROW)
Company Performance

Current Price

as of Oct 16, 2024

$54.82

P/E Ratio

N/A

Market Cap

$1.95B

Description

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Metrics

Overview

  • HQNashville, TN
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerHROW
  • Price$54.82+2.49%

Trading Information

  • Market Cap$1.95B
  • Float85.52%
  • Average Daily Volume (1m)477,673
  • Average Daily Volume (3m)576,036
  • EPS-$0.95

Company

  • Revenue$154.15M
  • Rev Growth (1yr)46.22%
  • Net Income-$6.47M
  • Gross Margin74.38%
  • EBITDA Margin9.67%
  • EBITDA$4.73M
  • EV$865.09M
  • EV/Revenue5.61
  • P/EN/A
  • P/S12.67
  • P/B33.49
Documents
SEC Filings
8-K (2024-09-09)
8-K (2024-08-07)
8-K (2024-06-26)
8-K (2024-06-17)
8-K (2024-05-13)
8-K (2024-03-21)
8-K (2024-03-20)
8-K (2024-03-19)
8-K (2024-02-15)
8-K (2024-01-29)
8-K (2024-01-03)
8-K (2023-11-13)
8-K (2023-11-03)
8-K (2023-09-29)
8-K (2023-08-09)
8-K (2023-07-21)
8-K (2023-07-18)
8-K (2023-06-23)
8-K (2023-05-11)
8-K (2023-03-28)
8-K (2023-03-23)
8-K (2023-01-23)
8-K (2023-01-12)
10-Q (2024-08-07)
10-Q (2024-05-13)
10-Q (2023-11-13)
10-Q (2023-08-09)
10-Q (2023-05-11)
10-K (2024-03-19)
10-K (2023-03-23)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-13)
Earnings Report (2023-08-09)
Factset
Factset Business Description
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Harrow, Inc Q3 ($12.83, 0.00) (2023-11-14T07:53:28Z)
Harrow, Inc reports Q3 EPS ($0.13) vs FactSet $0.04 [3 est, ($0.05)-0.15] ($13.00, 0.00) (2023-11-14T11:47:29Z)
Harrow completes transfer of TRIESENCE NDA ($9.00, 0.00) (2023-11-29T12:07:17Z)
Harrow completes transfer of NDAs and launches FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, and ZERVIATE in the U.S. ($14.14, 0.00) (2023-10-24T11:09:51Z)
Wikipedia
Harrow_Health